The difficulties of managing severe hepatitis B virus reactivation

  title={The difficulties of managing severe hepatitis B virus reactivation},
  author={Bruno Roche and Didier Samuel},
  journal={Liver International},
Reactivation of hepatitis B is characterized by a sudden increase in hepatitis B virus (HBV) replication in a patient with prior evidence of resolved or inactive HBV infection. Although HBV reactivation can occur spontaneously, it usually occurs after chemotherapy, immunosuppression (organ transplantation) or an alteration in immune function (therapy for autoimmune disease, human immunodeficiency virus infection). The clinical presentation cases can vary, ranging from a subclinical… 
Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.
This review article will focus on when to treat, when to monitor, what patients should receive HBV therapy, and what drugs should be selected for each scenario based on both current and different HBV management guidelines.
Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B.
  • P. Puri
  • Medicine, Biology
    Journal of clinical and experimental hepatology
  • 2013
Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
HBV screening is strongly recommended for co-infected HCV/HBV patients before initiation and during DAA therapy regardless of HBV status, HCV genotype and class of DAAs used, and HBV reactivation may occur regardless of HCV Genotype and type of DAA regimen.
Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents
The management of rheumatology patients with HBV and HCV infection is discussed with a focus on whom to screen and whom to treat to prevent consequences of these often unrecognized conditions.
Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience.
Patients with hematological malignancies and serological signs of prior resolved hepatitis B.
The event of HBV reactivation in patients with signs of resolved HBV infection undergoing treatment for HM is examined and possible management strategies are proposed.
Clinical and epidemiological patterns of HBV reactivation in the OBI group compared to the HBV reactsivation in HBsAg positive patients (non-OBI group) during chemoimmunotherapy for HM are evaluated.
Reactivation and Flare of Chronic Hepatitis B: Natural History, Diagnosis, Therapy and Prevention
In countries with intermediate or high endemicity for HBV, compounded in use cytotoxic or immunosuppressive therapy for the treatment of a wide variety of clinical disease, reactivation or fl are may be the first presentation of HBV infection.
Hepatitis B Virus Belated Reverse Sero-conversion After Hematopoietic Stem Cell Transplantation or Rituximab Chemotherapy
Close follow-up of patients forHBV reverse sero-conversion even in late stages after immune suppressive and anti-cancer treatments or HSCT seems beneficial, especially in regions with intermediate or high endemicity for HBV.


Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies
Overt and occult HBV pose a serious, but preventable, threat to haematology patients, particularly prior to chemotherapy, and pre‐treatment screening of patients at risk should be practiced diligently by all clinicians that treat patients with malignancies.
Managing HBV in patients with impaired immunity
The combination prophylaxis of passive immunisations with hepatitis B immunoglobulins (HBIG) and nucleos(t)ide analogues (NUC) is able to reduce HBV recurrence rates after transplantation to 0–10%.
Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and management
Pre‐emptive treatment of chronic hepatitis B patients undergoing cytotoxic or immunosuppressive therapy, with potent nucleoside analogues has shown some promising results, but further controlled studies are needed to define the incidence and risk factors of hepatitis B reactivation.
Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal.
HBV reactivation after kidney transplantation.
Hepatitis B in the HIV-Coinfected Patient
  • Y. Benhamou
  • Biology, Medicine
    Journal of acquired immune deficiency syndromes
  • 2007
The immune restoration associated with highly active antiretroviral therapy (HAART) can improve control of HBV replication but can also lead to increased immune-mediated liver injury, and use of HAART before severe immunosuppression develops may be beneficial.
Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
  • W. Yeo, T. Chan, P. Chan
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
Close monitoring until at least 6 months after anticancer therapy is required, with an alternative approach of prophylactic antiviral therapy to prevent this potentially fatal condition.
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
This review considers the diagnosis, prevention, and management of HBV reactivation in association with chemotherapy and hematopoietic stem cell transplantation, particularly in light of the availability of effective prophylactic antiviral therapy.